Regulatory News
Friday, May 13, 2016
BRIEF-Edge Therapeutics says received FDA fast-track designation for drug to treat subarachnoid hemorrhage
* Expects to begin enrollment in mid-2016, a pivotal phase 3
multi-center, multi-national, randomized, double-blind,
placebo-controlled, parallel-group study
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment